BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19560189)

  • 1. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
    Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
    Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
    Janco JM; Hacker MR; Konstantinopoulos PA; Cannistra SA; Awtrey CS
    J Minim Invasive Gynecol; 2011; 18(5):629-33. PubMed ID: 21803662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
    Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
    Black D; Levine DA; Nicoll L; Chou JF; Iasonos A; Brown CL; Sonoda Y; Chi DS; Leitao MM; Abu-Rustum NR; Ferguson SE; Barakat RR
    Gynecol Oncol; 2008 Apr; 109(1):39-42. PubMed ID: 18234300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system.
    Almadrones L; Yerys C
    Oncol Nurs Forum; 1990; 17(1):75-80. PubMed ID: 2300507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications associated with intraperitoneal chemotherapy catheters.
    Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
    Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters.
    Henretta MS; Anderson CL; Angle JF; Duska LR
    Gynecol Oncol; 2011 Nov; 123(2):342-5. PubMed ID: 21840583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
    Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
    Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
    Lan C; Li Y; Liu J
    Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
    Kehoe SM; Williams NL; Yakubu R; Levine DA; Chi DS; Sabbatini PJ; Aghajanian CA; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2009 May; 113(2):228-32. PubMed ID: 19254808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.
    Arts HJ; Willemse PH; Tinga DJ; de Vries EG; van der Zee AG
    Gynecol Oncol; 1998 Apr; 69(1):32-5. PubMed ID: 9570995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications.
    Lesnock JL; Richard SD; Zorn KK; Krivak TC; Beriwal S; Sukumvanich P; McBee WC; Kelley JL; Edwards RP
    Gynecol Oncol; 2010 Mar; 116(3):345-50. PubMed ID: 19959211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
    Malmström H; Carstensen J; Simonsen E
    Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
    Battelli C; Campo M; Buss MK; Awtrey CS; Konstantinopoulos PA
    Chemotherapy; 2013; 59(4):251-9. PubMed ID: 24457572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.